Clinical and Translational Studies: Office of Psychiatric Research

The Office of Psychiatric Clinical Research is designed to support psychiatric research in the clinical setting here at the Department of Psychiatry and Behavioral Neurobiology.  Our research division offers several cutting edge resources for Phase II, III and IV studies.  The coordination of our clinical trials is of the highest quality.  We are supported by experienced investigators and staff dedicated to academic excellence and quality patient care.  We have a full-time clinical research staff with regulatory and administrative services and assistance in designing clinical studies and providing referrals for statistical analysis.  We provide investigator training in psychiatric rating scales and standardized diagnostic instruments and education in patient recruitment.  We have a quality assurance program and facilities for drug storage, physical exams, EKG’s, interviewing, venipuncture and specimen processing. 

Our expert research team consists of:

Roberta May, MA, CCRC – Director; Hollis Ryan, BS, CCRC – Clinical Trials Manager; Samantha White, BS – Clinical Trials Administrator; Emily Hammond, M.Ed. – Clinical Trials Specialist; Sherer Thomson, M.Ed.- Clinical Trials Specialist; Nick Bossaller, BA – Clinical Trials Specialist; Brittny White, MS - Clinical Trials Specialist; Courtney Blair, MA - Research Assistant.

Currently Enrolling Trials:

ADHD

“Evening use of polarized glasses designed to filter out blue light in ADHD-Delayed Circadian Rhythm Disordered patients”  Principal Investigator: Rachel Fargason, MD

"Actigraphy Study of sleep in Adults with ADHD Treated with Bright Light Therapy" Principal Investigator: Rachel Fargason, MD

 Mood Disorders

 “Paliperidone and Lithium in the Treatment of Suicidality – Treatment Indication and Epigenetic Regulation” Principal Investigator:  Richard Shelton, MD

 “A three-phase study designed to test the efficacy, tolerability and safety of the combination of Ziprasidone with the selective serotonin reuptake inhibitor (SSRI) Escitalopram for patients with Major Depressive Disorder (MDD) that do not sufficiently respond to treatment with Escitalopram” Principal Investigator: Richard Shelton, MD

“A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of ketamine in subjects with treatment-resistant depression”  Principal Investigator: Richard Shelton, MD 

" A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder" Principal Investigator: Richard Shelton, MD

" A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects with Inadequate/Partial Response to Antidepressants during the Current Episode of Major Depressive Disorder" Principal Investigator: Richard Shelton, MD

" A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy in the Treatment Acute Depressive Episodes Associated with Bipolar 1 Disorder in Adult Subjects (TAK375SL_201)" Principal Investigator: Richard Shelton, MD

" A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects (TAK375SL_203)" Principal Investigator: Richard Shelton, MD

" A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder (ELND005-BPD201)" Principal Investigator: Richard Shelton, MD

"Oxidative Stress Mechanisms in Mood Disorders" Principal Investigator: Richard Shelton, MD

“A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of desvenlafaxine succinate sustained-release (DVS SR) in the treatment of children and adolescent outpatients with major depressive disorder” Principal Investigator: James T. Cullinan, DO

“A 6-month, open-label, multi-center, flexible-dose extension study to the B2061032 study to evaluate the safety, tolerability and efficacy of desvenlafaxine succinate sustained-release (DVS SR) tablets in the treatment of children and adolescent outpatients with major depressive disorder”  Principal Investigator: James T. Cullinan, DO

Other Enrolling Studies

"Circadian Misalignment in Shift Work Nurses" Principal Investigator: Karen Gamble, PhD

"Psychiatric Biological Samples Repository" Principal Investigator: Richard Shelton, MD

Healthy Volunteers

We have some studies that require Healthy Volunteers. Please contact us to find out what we have available.  

 

For further information, please contact:
UAB Department of Psychiatry
Office of Psychiatric Clinical Research
1720 7th Avenue South
Sparks Building, 10th Floor
Birmingham, AL 35294-0017
Telephone:  (205) 934-2484
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.